Science magazine has called the Lake Geneva Region the “Number One cluster for life sciences research in continental Europe”. The biotech and medtech sectors in BioAlps are experiencing double-digit annual growth. Geneva’s competence in pharmaceuticals, chemistry, biotechnology, microtechnology, precision instruments and medical devices continues to attract multinational healthcare and life science companies.
Geneva offers many assets for the continued development of this sector: well-known existing companies attract newcomers, while the science and technology focus of Geneva’s universities, graduate schools, R&D facilities and technology centers ensures that research remains at the cutting edge.
Geneva’s hospitals, clinics and medical schools welcome cooperation with industry. Incubators like Eclosion and Fongit, as well as Geneva’s favorable conditions for new businesses and start-ups, provide additional encouragement. Finally, the ever-increasing collaboration in the medical technology and biomedical fields between Western Switzerland – known as the BioAlps region – and the Rhône-Alpes region of France adds to the sector’s critical mass.
In terms of scientific publications, the University of Geneva has been ranked second in the field of Molecular Biology & Genetics – just after Massachusetts Institute of Technology (MIT).
The Swiss National Science Foundation has attributed three national research projects related to the life sciences to teams at the University of Geneva.
Three National Centers of Competence in Research (NCCR) hosted by University of Geneva:
- Materials with novel electronic properties (MaNEP) - (electronic materials for the future, which might be used in bioconvergent applications)
- Affective Sciences
- Frontiers in Genetics
In order to promote research and teaching in the field of Genome Sciences, the University of Geneva has established a new interfaculty institute, the Institute of Genetics and Genomics in Geneva (iGE3), tasked with building bridges between basic and clinical research by providing a single organizational structure to 50 research groups.
In addition, Geneva is one of the 3 Clinical Trial Units, together with Basel and Bern, recognized by the Swiss National Fund. It is a national center of competence for phase I to III clinical research. Clinical research is conducted by the University Hospitals of Geneva in collaboration with major pharmaceutical companies.
« Using our life science know-how and technologies, BioAlps speeds up your access to an interdisciplinary community and an innovative business environment with all the ingredients for success. »
Benoît Dubuis, President, BioAlps
« The Eclosion incubator offers specialized knowledge both from the business and life sciences point of view, and an advisory board covering all the different areas from regulatory to commercialization. Our high value-added labs offer the complete infrastructure needed for early development and we have the necessary contacts and support in the region to access to specific services when required. »
Jesus Martin-Garcia, Director, Eclosion
Geneva is part of BioAlps, the fastest growing life science cluster in the world. The BioAlps cluster ranks among the first three European centers for research in biotechnology and medical technologies, alongside Cambridge and Oxford in the United Kingdom.
- 750 biotechnology, pharma and medtech companies
- 500 research laboratories
- 20 research institutions, universities and university hospitals with relevant capabilities and expertise
- Numerous organizations supporting innovation (start-up incubators, science parks, venture capital funds, contract service organizations)
- 20,000 people employed in companies and 5,000 researchers